Patient-reported outcomes before and after treatment of major depressive disorder
Patient-reported outcomes before and after treatment of major depressive disorder
复制标题
重度抑郁症治疗前后患者报告的结果
DOI：
--
复制
发表时间：
2014
影响因子：
8.3
通讯作者：
R. Cohen
中科院分区：
文献类型：
--
作者：
W. Ishak;J. Mirocha;Sarah Pi;Gabriel Tobia;Bret Becker;E. Peselow;R. Cohen
患者报告的生活质量（QoL）、功能和抑郁症状严重程度的结局（PRO）在评估重度抑郁症（MDD）的疾病负担和评价治疗效果方面非常重要。我们试图提供一个详细的分析PRO治疗前和治疗后的大型序贯治疗替代缓解抑郁症（星星 * D）研究。该分析检查了治疗前后星星 * D第二级的PRO。分析了每种星星 * D 2级治疗的QoL、功能和抑郁症状严重程度的完整数据。在使用西酞普兰（1级）进行的选择性5-羟色胺再摄取抑制剂试验失败后，生活质量、功能和抑郁症状严重程度的PRO显示出实质性损害。2级中的7种治疗选择对QoL、功能、抑郁症状严重程度和计算的疾病负担降低具有统计学（P值）和临床（Cohen标准化差异[Cohen d]）显著影响。干预措施之间没有统计学显著差异。然而，相当一部分患者在治疗后仍有患者报告的生活质量和功能障碍，这种影响在非缓解者中更为明显。PRO对于理解MDD的影响以及检查研究和临床环境中治疗干预的效果至关重要。
Patient reported outcomes (PROs) of quality of life (QoL), functioning, and depressive symptom severity are important in assessing the burden of illness of major depressive disorder (MDD) and to evaluate the impact of treatment. We sought to provide a detailed analysis of PROs before and after treatment of MDD from the large Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. This analysis examines PROs before and after treatment in the second level of STAR*D. The complete data on QoL, functioning, and depressive symptom severity, were analyzed for each STAR*D level 2 treatment. PROs of QoL, functioning, and depressive symptom severity showed substantial impairments after failing a selective serotonin reuptake inhibitor trial using citalopram (level 1). The seven therapeutic options in level 2 had positive statistically (P values) and clinically (Cohen's standardized differences [Cohen's d]) significant impact on QoL, functioning, depressive symptom severity, and reduction in calculated burden of illness. There were no statistically significant differences between the interventions. However, a substantial proportion of patients still suffered from patient-reported QoL and functioning impairment after treatment, an effect that was more pronounced in nonremitters. PROs are crucial in understanding the impact of MDD and in examining the effects of treatment interventions, both in research and clinical settings.
登录
查看更多内容
DOI：
10.1016/s0197-2456(03)00112-0
发表时间：
2004-02-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
Rush, AJ;Fava, M;Niederehe, G
通讯作者：
Niederehe, G
影响因子：
7.2
作者：
Cella, David;Riley, William;Stone, Arthur;Rothrock, Nan;Reeve, Bryce;Yount, Susan;Amtmann, Dagmar;Bode, Rita;Buysse, Daniel;Choi, Seung;Cook, Karon;DeVellis, Robert;DeWalt, Darren;Fries, James F.;Gershon, Richard;Hahn, Elizabeth A.;Lai, Jin-Shei;Pilkonis, Paul;Revicki, Dennis;Rose, Matthias;Weinfurt, Kevin;Hays, Ron
通讯作者：
Hays, Ron
恩迪科特工作生产力量表（EWPS）：评估治疗效果的新措施。
DOI：
--
发表时间：
1997
期刊：
Psychopharmacology bulletin.
影响因子：
--
作者：
Endicott,J;Nee,J
通讯作者：
Nee,J
DOI：
10.2471/blt.09.067231
发表时间：
2010-11-01
期刊：
Bulletin of the World Health Organization: International Journal of Public Health
影响因子：
--
作者：
Üstün, T Bedirhan;Chatterji, Somnath;Pull, Charles
通讯作者：
Pull, Charles
DOI：
10.1176/ps.48.2.224
发表时间：
1997
期刊：
Psychiatric services (Washington, D.C.)
影响因子：
--
作者：
Pyne,JM;Patterson,TL;Kaplan,RM;Gillin,JC;Koch,WL;Grant,I
通讯作者：
Grant,I